Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 4/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18939169 | 0.88 | SLC22A12 (0.45) | SLC22A12METRPS6KA5RORCGRIN2B | |
| SCHEMBL18960813 | 0.85 | SLC22A12 (0.38) | SLC22A12METRPS6KA5RORCGRIN2B | |
| Hydrochloric Acid SCHEMBL18938985 | 0.84 | SLC22A12 (0.37) | SLC22A12METRPS6KA5RORCGRIN2B | |
| SCHEMBL18967497 | 0.83 | SLC22A12 (0.36) | SLC22A12METRPS6KA5RORCGRIN2B | |
| SCHEMBL18977649 | 0.81 | PLAU (0.46) | PLAUMETPLGGRIN2B | |
| SCHEMBL18977913 | 0.81 | GRIN2B (0.43) | SLC22A12METRPS6KA5GRIN2BNR3C1 | |
| SCHEMBL18939270 | 0.79 | PLAU (0.46) | PLAUSLC22A12PLGRORC | |
| SCHEMBL18960814 | 0.79 | SLC22A12 (0.37) | SLC22A12METRORCGRIN2BNR3C1 | |
| SCHEMBL18939019 | 0.78 | PLAU (0.48) | PLAUSLC22A12PLG | |
| SCHEMBL18939091 | 0.78 | RPS6KA5 (0.41) | SLC22A12METRPS6KA5GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108463461-B | Cephem compounds, their preparation and use | 奈加-RGM制药有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| WO-2017096472-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | PLAU 4395/4885SLC22A12 2800/4885MET 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.